Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gabriel Steg

Showing results (81-90 of 242) with videos related to

Pageof 25
Sort By:
Archives of Cardiovascular Diseases|July 31, 2023
Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registryJeremie Abtan, Gregory Ducrocq, Yedid Elbez, et al.
Journal of the American College of Cardiology|August 15, 2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisMichelle O'Donoghue, Elliott M Antman, Eugene Braunwald, et al.
European Heart Journal|November 11, 2022
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54Marc P Bonaca, KyungAh Im, Giulia Magnani, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|January 20, 2022
Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT StudyNino Mihatov, Eric A Secemsky, Dean J Kereiakes, et al.
Archives of Internal Medicine|February 25, 2009
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary EventsPeter R Sinnaeve, P Gabriel Steg, Keith A A Fox, et al.
Circulation. Cardiovascular Interventions|October 26, 2018
Benefit and Risk of Prolonged DAPT After Coronary Stenting in WomenNatalia C Berry, Dean J Kereiakes, Robert W Yeh, et al.
International Journal of Cardiology|May 8, 2012
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortalityRonan Roussel, Samy Hadjadj, Blandine Pasquet, et al.
American Heart Journal|March 30, 2006
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study designE Magnus Ohman, Deepak L Bhatt, P Gabriel Steg, et al.
Journal of the American College of Cardiology|April 22, 2026
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical TrialAlberico L Catapano, Elina Mikhailova, Ann Marie Navar, et al.
Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.
Pageof 25

Showing results (81-90 of 242) with videos related to

Sort By:
Pageof 25
Archives of Cardiovascular Diseases|July 31, 2023
Association between coffee or tea consumption and cardiovascular outcomes in patients with stable coronary artery disease: Analysis from the CLARIFY registryJeremie Abtan, Gregory Ducrocq, Yedid Elbez, et al.
Journal of the American College of Cardiology|August 15, 2009
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysisMichelle O'Donoghue, Elliott M Antman, Eugene Braunwald, et al.
European Heart Journal|November 11, 2022
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54Marc P Bonaca, KyungAh Im, Giulia Magnani, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|January 20, 2022
Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT StudyNino Mihatov, Eric A Secemsky, Dean J Kereiakes, et al.
Archives of Internal Medicine|February 25, 2009
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary EventsPeter R Sinnaeve, P Gabriel Steg, Keith A A Fox, et al.
Circulation. Cardiovascular Interventions|October 26, 2018
Benefit and Risk of Prolonged DAPT After Coronary Stenting in WomenNatalia C Berry, Dean J Kereiakes, Robert W Yeh, et al.
International Journal of Cardiology|May 8, 2012
Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortalityRonan Roussel, Samy Hadjadj, Blandine Pasquet, et al.
American Heart Journal|March 30, 2006
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study designE Magnus Ohman, Deepak L Bhatt, P Gabriel Steg, et al.
Journal of the American College of Cardiology|April 22, 2026
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical TrialAlberico L Catapano, Elina Mikhailova, Ann Marie Navar, et al.
Circulation|November 26, 2009
Smoking, clopidogrel, and mortality in patients with established cardiovascular diseaseJeffrey S Berger, Deepak L Bhatt, Steven R Steinhubl, et al.
Pageof 25